SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced that a poster was presented today at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, MA. The poster, which was selected as a Presidential Poster of Distinction, placing it in the top 10% of those selected for presentation, provides data from a preclinical study for MB07811, the Company’s clinical-stage liver-targeted beta-subtype-selective thyroid hormone receptor (TRß) agonist product candidate for the treatment of hyperlipidemia.
